EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation

Srividya Velagapudi iD, Melroy X Miranda, Priyanka Adla, Simon Kraler iD, Shafeeq A Mohammed, Shekhar Baki, Jerome Robert, Lucia Rohrer, Hwan Lee, Hyun-Duk Jang iD, Slayman Obeid, Anne Tailleux und 9 weitere

Cardiovascular Research · 14.07.2025

DOI: 10.1093/cvr/cvaf087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 14.07.2025. Verfasst von Srividya Velagapudi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Cardiology, University of Zürich, Schlieren Campus, Switzerland. Hauptthemen laut MEDLINE: Sirtuin 1, Proprotein Convertase 9, Receptors, LDL, Liver. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Research Foundation, Swiss Heart Foundation, Theodor Ida Herzog-Egli Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Low-density lipoprotein (LDL)-cholesterol is causally involved in atherosclerotic cardiovascular disease (ASCVD) pathogenesis. Pharmacological activation of the intracellular NAD + -dependent deacetylase Sirtuin-1 (SIRT1) reduces plasma LDL-cholesterol levels by increasing hepatic LDL-receptor (LDLR) expression, which intriguingly associates with atheroprotective effects. Recent studies have identified the presence of SIRT1 in plasma, however, its effects remain elusive. We found that plasma levels of SIRT1 to be decreased in atherosclerotic mice compared with wild-type controls and aimed to investigate the therapeutic potential of systemic SIRT1 restoration on lipid metabolism and plaque burden in atherosclerotic mice and dissect the underlying molecular mechanisms involved. Methods and results Twelve-week-old apolipoprotein E-deficient (ApoE−/−) mice fed a high-cholesterol diet (1.25% w/w) were randomized to receive recombinant murine SIRT1(rmSIRT1) (n = 6; 0.3 mg/kg BW i.p.) or vehicle (n = 6; PBS) every third day over 4 weeks. Boosting systemic SIRT1 levels increased hepatic LDLR protein expression, reduced plasma LDL-cholesterol levels and decreased plaque progression in ApoE−/− mice. Yet, rmSIRT1 treatment did not change hepatic proprotein convertase subtilisin/kexin type 9 (PCSK9) expression but notably increased its deacetylated levels. Mechanistically, rmSirt1 directly bound to hepatic PCSK9 thereby promoting PCSK9 deacetylation involving 3 sites, namely Lys243, Lys421, and Lys506, as shown by mass spectrometric analyses. In vitro mutagenesis to triple deacetylation mimetic (3KR) reduced SIRT1-induced PCSK9 activity, as evidenced by increased cellular binding and association of 125I-LDL to hepatic LDLR. Finally, plasma levels of SIRT1 and PCSK9 were assessed at baseline in patients with acute coronary syndromes. In these patients, plasma SIRT1 levels correlated inversely with PCSK9 with high SIRT1 levels conferring a reduced risk of major adverse cardiovascular events (MACE).

Conclusion

SIRT1 directly binds hepatic PCSK9 and decreases its activity by deacetylation, thereby enhancing LDL-cholesterol clearance by hepatic LDLR upregulation. Boosting circulating SIRT1 exerts atheroprotective effects in mice, with high levels associating with improved prognosis in patients with established ASCVD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sirtuin 1Proprotein Convertase 9Receptors, LDLLiverAtherosclerosisAortic DiseasesAnimalsPlaque, AtheroscleroticMice, Knockout, ApoEDisease Models, AnimalHumansMice, Inbred C57BLCholesterol, LDLMaleAcetylationProteolysisProtein BindingSignal TransductionHep G2 Cells

Stichwörter der Autor:innen

AtherosclerosisHepatic LDLRLDL-cholesterolPCSK9Post-translational modificationSirtuin-1

Substanzen

Sirtuin 1Proprotein Convertase 9Receptors, LDLPcsk9 protein, mouseSirt1 protein, mouseCholesterol, LDLPCSK9 protein, humanSIRT1 protein, humanLDLR protein, human

Autor:innen und Institutionen

  • Center for Molecular Cardiology, University of Zürich, Schlieren Campus, Switzerland.
  • Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, India.
  • Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, Zurich University Hospital and University of Zürich, Zürich, Switzerland.
  • Institute of Clinical Chemistry, University Hospital Zürich, Zürich, Switzerland.
  • Biomedical Research Institute, Seoul National University Hospital, Seoul, S.Korea.
  • Department of Cardiology, University Hospital Zürich, Zürich, Switzerland.

ORCID-Profile: Srividya Velagapudi, Simon Kraler, Hyun-Duk Jang, Bart Staels, Francesco Paneni, Hyo-Soo Kim, Alexander Akhmedov, Thomas F Lüscher

Förderung

  • Swiss National Research Foundation
  • Swiss Heart Foundation
  • Theodor Ida Herzog-Egli Foundation
  • Lindenhofstiftung
  • Forschungskredit Postdoc grant
  • Holcim Stiftung grant
  • Foundation for Cardiovascular Research
  • National Research Foundation of Korea

Zitieren

APA

Velagapudi, S., Miranda, M. X., Adla, P., Kraler, S., Mohammed, S. A., Baki, S., Robert, J., Rohrer, L., Lee, H., Jang, H. D., Obeid, S., Tailleux, A., Staels, B., Sepuri, N. B. V., Paneni, F., Gutti, R. K., von Eckardstein, A., Kim, H. S., Akhmedov, A., …, & Lüscher, T. F. (2025). Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf087

Vancouver

Velagapudi S, Miranda MX, Adla P, Kraler S, Mohammed SA, Baki S, et al. Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf087

BibTeX
@article{Velagapudi2025,
  author = {Velagapudi, Srividya and Miranda, Melroy X and Adla, Priyanka and Kraler, Simon and Mohammed, Shafeeq A and Baki, Shekhar and Robert, Jerome and Rohrer, Lucia and Lee, Hwan and Jang, Hyun-Duk and Obeid, Slayman and Tailleux, Anne and Staels, Bart and Sepuri, Naresh Babu V and Paneni, Francesco and Gutti, Ravi Kumar and von Eckardstein, Arnold and Kim, Hyo-Soo and Akhmedov, Alexander and Camici, Giovanni G and Lüscher, Thomas F},
  title = {Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation},
  journal = {Cardiovascular Research},
  year = {2025},
  doi = {10.1093/cvr/cvaf087}
}
Kostenlos starten →